** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 2% to $62.70

** Co says the U.S. FDA has given expanded approval for Iluvien to treat chronic, non-infectious uveitis affecting the posterior segment of the eye (NIU-PS)

** NIU-PS is characterized by inflammation of the retina or optic nerve of the eye

** Iluvien is already approved by the FDA to treat another eye condition called diabetic macular edema $(DME.AU)$

** Co plans to market Iluvien under the combined label in the U.S. later this year

** Up to last close, ANIP has fallen 7.2% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))